Karl Kuhn, MD
Pulmonary Disease · Nashville, TNNPI 1003876236
Payments from drug & device makers
Across 369 payments — averaging $286.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$100K
- AstraZeneca$1K
- GSK$681
- Actelion Pharmaceuticals US, Inc.$458
- Boehringer Ingelheim$330
- Insmed, Inc.$268
- plus $2K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 153 | $100,300 |
| AstraZeneca | 46 | $1,326 |
| GSK | 39 | $681 |
| Actelion Pharmaceuticals US, Inc. | 15 | $458 |
| Boehringer Ingelheim | 14 | $330 |
| Insmed, Inc. | 13 | $268 |
| Inspire Medical Systems, Inc. | 6 | $268 |
| Amgen | 6 | $231 |
| Philips North America LLC | 5 | $183 |
| Jazz Pharmaceuticals Inc. | 6 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $152 |
| Baxter Healthcare | 4 | $137 |
| Regeneron Healthcare Solutions, Inc. | 6 | $129 |
| Advanced Respiratory, Inc | 6 | $107 |
| Pfizer | 5 | $105 |
| CSL Behring | 5 | $99 |
| United Therapeutics Corporation | 4 | $97 |
| Sanofi | 3 | $89 |
| Mylan Specialty L.p. | 4 | $62 |
| Johnson & Johnson | 2 | $61 |
| Verona Pharma, Inc. | 2 | $56 |
| Harmony Biosciences LLC | 2 | $53 |
| Electromed, Inc. | 3 | $46 |
| Vifor Pharma, Inc. | 1 | $36 |
| Fisher & Paykel Healthcare Inc | 1 | $35 |
| 3b Medical, Inc. | 1 | $30 |
| Tactile Systems Technology Inc | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $29 |
| Grifols USA, LLC | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Viatris Specialty LLC | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
$105,764 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Nashville
- Fabien MaldonadoNashville$2.5M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Otis RickmanNashville$426K
- Jonathan KropskiNashville$419K
- Justin HewlettNashville$388K
- Susan GarwoodNashville$351K
- Margaret SalisburyNashville$345K
- Joao DeandradeNashville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.